科研之友
微信
新浪微博
Facebook
分享链接
摘要
The existing drugs for treatment of osteoporosis are limited in scope, tolerability, and efficacy. Newer osteoclast-targeted agents like inhibitors of receptor activator nuclear factor kappa B pathway, Cathepsin K, and integrins are under clinical development. Osteoblast-targeted therapies include the agents acting through the Wnt signaling pathway like sclerostin antagonists. The potential molecular targets and the emerging drugs for treatment of osteoporosis are discussed in this review.
- 出版日期2010-4
